Successful control of an outbreak of invasive aspergillosis in a regional haematology unit during hospital construction works

Journal of Hospital Infection

Volumn 69, Issue 1, 2008, Pages 33-38

  Chang, C C ^a   Cheng, A C ^a   Devitt, B ^a   Hughes, A J ^a   Campbell, P ^a   Styles, K ^a   Low, J ^a   Athan, E ^a  

^a GEELONG HOSPITAL   (Australia)

Author keywords

Aspergillosis; Construction; Haematology; Outbreak; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; VINCA ALKALOID; VINCRISTINE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ARCHITECTURAL BARRIER; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOPSY; BRONCHOSCOPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTRUCTION WORK; EPIDEMIC; FACE MASK; HEALTH CARE PERSONNEL; HEMATOLOGY; HIGH RISK PATIENT; HOSPITAL BUILDING; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LOADING DRUG DOSE; LUNG BIOPSY; LYMPHOMA; MULTIPLE CYCLE TREATMENT; PATIENT TRANSPORT; POLYMERASE CHAIN REACTION; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; SPUTUM ANALYSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHEMOPREVENTION; CROSS INFECTION; DISEASE OUTBREAKS; ENVIRONMENTAL EXPOSURE; HEMATOLOGY; HOSPITAL DESIGN AND CONSTRUCTION; HOSPITAL UNITS; HUMANS; INFECTION CONTROL; PYRIMIDINES; TRIAZOLES;

EID: 42649137532     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2008.02.010     Document Type: Article

References (22)

1. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
2. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Morb Mortal Wkly Rep 49 (2000) 1-128
3. McCann S., Byrne J.L., Rovira M., et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 33 (2004) 519-529
4. Prentice H.G., Kibbler C.C., and Prentice A.G. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110 (2000) 273-284
5. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
6. Halliday C., Wu Q.X., James G., and Sorrell T. Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol 43 (2005) 5366-5368
7. Streifel A.J. In with the good air. Infect Control Hosp Epidemiol 23 (2002) 488-490
8. Vonberg R.P., and Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 63 (2006) 246-254
9. Centers for Disease Control and Prevention. Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morb Mort Wkly Rep 52 (2003) 1-48
10. Policy Number 10.4. Construction Renovation and Maintenance. Infection Prevention and Control Manual. 2nd edn (2005), Rural Infection Control Practice Group, Victoria
11. Anderson K., Morris G., Kennedy H., et al. Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air. Thorax 51 (1996) 256-261
12. HCAMC in association with UNSW. Part D: infection Control and Prevention. Australasian Health Facility Guidelines [Revision v.1.0]; 2007. p. 637-660.
13. Sehulster L.M., Chinn R.Y.W., Arduino M.J., et al. Guidelines for environmental infection control in health-care facilities. Recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) (2004), American Society for Healthcare Engineering/American Hospital Association, Chicago
14. Fitzpatrick F., Prout S., Gileece A., Fenelon L.E., and Murphy O.M. Nosocomial aspergillosis during building work - a multidisciplinary approach. J Hosp Infect 42 (1999) 170-171
15. Hahn T., Cummings M., Michalek A., Lipman B., Segal B., and McCarthy P.L. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with haematologic malignancies. Infect Control Hosp Epidemiol 23 (2002) 525-531
16. Loo V.G., Bertrand C., Dixon C., et al. Control of construction-associated nosocomial Aspergillosis in an antiquated haematological unit. Infect Control Hosp Epidemiol 17 (1996) 360-364
17. Opal S.M., Asp A.A., Cannady Jr. P.B., Morse P.L., Burton L.J., and Hammer II P.G. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 153 (1986) 634-637
18. Eckmanns T., Ruden H., and Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunocompromised patients: a systemic review. J Infect Dis 193 (2006) 1408-1418
19. Cordonnier C., Maury S., Pautas C., et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transpl 33 (2004) 943-948
20. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
21. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
22. McLintock L.A., Jornaides N.E., Allan E.K., et al. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 124 (2004) 403-404